| Saurabh Sachan, | |
|
294 Summar Dr, Jackson, TN 38301-3915 | |
| (731) 423-1932 | |
| (731) 410-0367 |
| Full Name | Saurabh Sachan |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 294 Summar Dr, Jackson, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225422637 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 57816 (Tennessee) | Primary |
| Entity Name | University Of Tennessee |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780686436 PECOS PAC ID: 3072421213 Enrollment ID: O20031119000671 |
News Archive
Introgen Therapeutics, Inc. today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex) marketed by Pfizer to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.
Although caregivers of patients with eating disorders usually experience a heavy caregiving burden, the effects of social support on caregivers of patients with eating disorders are unknown.
Gastroesophageal reflux disease (GERD) is the most common esophageal disorder, and frequently encountered in the primary care setting. Accumulating evidence has confirmed the excellent efficacy and safety of proton pump inhibitor (PPI) therapy in patients with all grades of GERD, making these agents the mainstay of treatment.
The PhytoLabs group of companies, holder of the world wide rights to the newly released University of Mississippi's immuno-stimulatory dietary supplement, is very pleased to announce that Patent #7,205,284 for Potent Immunostimulants from Microalgae has been issued by the U.S. Patent and Trademark Office (USPTO).
› Verified 2 days ago
| Entity Name | Emergency Medical Care Facilities Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538345855 PECOS PAC ID: 6103837877 Enrollment ID: O20060509000565 |
News Archive
Introgen Therapeutics, Inc. today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex) marketed by Pfizer to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.
Although caregivers of patients with eating disorders usually experience a heavy caregiving burden, the effects of social support on caregivers of patients with eating disorders are unknown.
Gastroesophageal reflux disease (GERD) is the most common esophageal disorder, and frequently encountered in the primary care setting. Accumulating evidence has confirmed the excellent efficacy and safety of proton pump inhibitor (PPI) therapy in patients with all grades of GERD, making these agents the mainstay of treatment.
The PhytoLabs group of companies, holder of the world wide rights to the newly released University of Mississippi's immuno-stimulatory dietary supplement, is very pleased to announce that Patent #7,205,284 for Potent Immunostimulants from Microalgae has been issued by the U.S. Patent and Trademark Office (USPTO).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Saurabh Sachan, 294 Summar Dr, Jackson, TN 38301-3915 Ph: (731) 423-1932 | Saurabh Sachan, 294 Summar Dr, Jackson, TN 38301-3915 Ph: (731) 423-1932 |
News Archive
Introgen Therapeutics, Inc. today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex) marketed by Pfizer to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.
Although caregivers of patients with eating disorders usually experience a heavy caregiving burden, the effects of social support on caregivers of patients with eating disorders are unknown.
Gastroesophageal reflux disease (GERD) is the most common esophageal disorder, and frequently encountered in the primary care setting. Accumulating evidence has confirmed the excellent efficacy and safety of proton pump inhibitor (PPI) therapy in patients with all grades of GERD, making these agents the mainstay of treatment.
The PhytoLabs group of companies, holder of the world wide rights to the newly released University of Mississippi's immuno-stimulatory dietary supplement, is very pleased to announce that Patent #7,205,284 for Potent Immunostimulants from Microalgae has been issued by the U.S. Patent and Trademark Office (USPTO).
› Verified 2 days ago
John Hayes, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 708 W Forest Ave, Jackson, TN 38301 Phone: 731-660-8755 Fax: 731-660-8739 | |
Dr. Donald Charles Correll, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 708 W Forest Ave, Jackson, TN 38301 Phone: 731-425-6280 Fax: 731-425-4922 | |
Dr. William Tyler Hayden, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 620 Skyline Dr, Jackson, TN 38301 Phone: 731-343-0886 | |
Dr. Keith Alden Mosher Jr., MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 21 Meridian Springs Dr, Jackson, TN 38301 Phone: 731-256-0526 Fax: 731-256-1720 | |
Jim C Craig Jr., M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 708 W Forest Ave, Jackson, TN 38301 Phone: 731-660-8759 | |
Jay Gordon Shires, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 294 Summar Dr, Jackson, TN 38301 Phone: 731-423-1932 Fax: 731-265-8355 | |
Dr. Robert D Turner, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 367 Hospital Blvd, Jackson, TN 38305 Phone: 731-661-2000 |